Trial Profile
A Prospective, Multicenter, Open Label, Single Arm, Phase 2 Study to Investigate the Safety, Tolerability and Pharmacokinetics of Selexipag in Children With Pulmonary Arterial Hypertension
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 28 Feb 2023 Planned End Date changed from 9 Dec 2026 to 31 Dec 2026.
- 01 Mar 2022 Planned primary completion date changed from 11 Feb 2026 to 29 Apr 2022.
- 01 Mar 2022 Status changed from recruiting to active, no longer recruiting.